Novel Coronavirus Information Center

Elsevier’s free health and medical research on the novel coronavirus (SARS-CoV-2) and COVID-19

January 27, 2020 - Updated July 14, 2021
3D illustration of Coronavirus (© istock.com/Dr_Microbe)
3D illustration of Coronavirus (© istock.com/Dr_Microbe)

Welcome to Elsevier's Novel Coronavirus Information Center. Here you will find expert, curated information for the research and health community on SARS-CoV-2 (the novel coronavirus) and COVID-19 (the disease).

All resources are free to access and include guidelines for clinicians and patients.

See our directory of all Elsevier's COVID-19 resources

For researchers

Under the Research tab, you will find a selection of the latest early-stage and peer-reviewed research on COVID-19 from journals including The Lancet and Cell Press. We have also made more than 63k related Elsevier journal articles and book chapters free to access on ScienceDirect and PubMedCentral.

These articles are also available to download over FTP with rights for full text and data mining, re-use and analyses for as long as needed.

  • Server address: coronacontent.np.elsst.com
  • Protocol: sftp (SSH File Transfer Protocol)
  • Username: public
  • Password: beat_corona

You will need to use FTP client software such as Cyberduck or WinSCP to access the FTP server.

Download full text for data mining

We share daily updates to this corpus with the Allen Institute for inclusion in the multi-publisher CORD-19 dataset.

For clinicians

Under the Clinical information tab, you will find evidence-based skill guides and care plans for treatment, safety and patient education, along with emergency prepared resources.

For patients

In the Patient resources section, you can find our 3D4Medical coronavirus video, resources from the CDC and WHO, and information about Elsevier's Patient Access Program for research.


Share your feedback to help us improve our Novel Coronavirus Information Center. And if you experience any accessibility problems with the site or content, please contact accessibility@elsevier.com.


Introduction

Introduction

Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier

As we enter 2021, the pandemic rages on, with much of the focus turning to vaccines. We recently added a Vaccine section to this information center, with guidance for clinicians. When we began this resource last January, we anticipated “an explosion of clinical and epidemiological information and research,” and we have certainly seen that. Our goal was to open whatever resources we could to help public health authorities, researchers and clinicians contain and manage this disease. We have provided — and continue to provide — regularly updated resources from Elsevier's content and experts. Our resources span scientific and medical journalseducational products, a clinically focused COVID-19 Healthcare Hub and periodic podcast interviews with internationally-recognized experts. There is a new R&D tool, and we have created an interactive global map of experts based on Scopus data.

Read more


Clinical information

In this section, you can find the following resources:

  • Guidelines: including new NIH and NICE guidelines; COVID-19 guidance on testing, drug therapy, ventilators, PPE, cardiovascular medicine and anesthesiology; and videos on medical procedures.
  • Elsevier Clinical Solutions: Clinical Overviews on ClinicalKey, Clinical Skills for Nursing, Interprofessional Care Plans and patient engagement resources
  • Mental and behavioral health: Guidance for anxiety and depression, including Patient Engagement videos

Elsevier COVID-19 Healthcare Hub

Gain access to our latest evidence-based practices and resources for COVID-19, covering topics from symptom management to diagnosis, treatment and ongoing wellness.

Podcast series

Podcast series

Expert Insights on COVID-19 with Elsevier

In Elsevier's podcast series for frontline clinicians and providers, experts share their insights into the mode of transmission and pathophysiology of the virus, how medical informatics and telemedicine are used to manage the pandemic, and best practices for emergency nursing crisis preparedness.

Listen to the podcasts

Guidelines

Guidelines for clinical practice, lab testing, equipment and more

View more

Elsevier Clinical Solutions

Guidance from ClinicalKey, Clinical Solutions Nursing, Interprofessional Practice and Patient Education

Vaccine guidelines

You can find more information on vaccines in Elsevier's COVID-19 Healthcare Hub Vaccine Toolkit:

Clinical Overviews on ClinicalKey are easy-to-scan clinically focused medical topic summaries designed to match the clinician workflow. Elsevier's Point-of-Care Editorial team develops them through a process that includes review and revision by a medical editor; peer reviews performed by subject matter experts; a production review to ensure consistency in style, grammar, and punctuation; and a final evaluation by the editor-in-chief.

View more

New book

Jie-Ming Qu, Bin Cao and Rong-Chang Chen: Covid-19: The Essentials of Prevention and Treatment (Elsevier, Oct 2020)

Mental and behavioral health

With the fear and uncertainty brought on by the pandemic — and calls for social distancing — many people are experiencing increased stress, anxiety and depression. Our evidence-based patient education resources support professional practice guidelines, presenting information in a way that is easy to understand and actionable. You can find more resources in Elsevier's COVID-19 Healthcare Hub.

Anxiety resources

Anxiety screening tool

Elsevier has created this anxiety screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 13 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.

Anxiety literature

Book chapters and peer-reviewed articles from Elsevier journals

View more

Depression resources

Depression screening tool

Elsevier has created this depression screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 18 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.

Clinical Skills

Clinical Overviews

Patient Education

Depression literature

Book chapters and peer-reviewed articles from Elsevier journals

Journal articles

View more

Related stories by Elsevier book authors

woman with mask in loneliness image

Chinese-language resources

中文资源

Resources from Elsevier's Clinical Solutions team in China

Date Title Published by (CN) Published by (EN) Link
  Virology 病毒学
1月24日 新型冠状病毒国家科技资源服务系统。共享:
1)第一株病毒毒种信息及其电镜照片
2)新型冠状病毒核酸检测引物和探针序列
国家微生物科学数据中心和国家病原微生物资源库 National Microbiological Data Center;
National Pathogen Resource Collection Center
http://nmdc.cn/#/nCoV

View more resources


Research

In this section, you can find the following resources:

Related articles freely available on ScienceDirect

Elsevier has made coronavirus-related articles and book chapters freely available for as long as is necessary, commencing in February 2020. This content is now freely available on ScienceDirect and PubMedCentral

The Lancet Coronavirus Hub

The Lancet's Coronavirus hub page brings together new coronavirus content from The Lancet journals as it is published.

Cell Press Coronavirus Resource Hub

On this Coronavirus Resource Hub, curated by members of the Cell Press editorial team, you'll find  content about the outbreak as it appears in Cell Press journals along with our policies for submitting papers.

1Science Coronavirus Research Repository

1science, acquired by Elsevier in 2018, was created to expand the scope of existing abstracting and analytics databases. It includes quality controlled academic and research documents in all disciplines and languages, from all countries. Its core index, 1findr, currently comprises more than 120 million metadata records, including over 30 million links to free full-text articles selected from about 100,000 referred scholarly journals. The Coronavirus Research Repository is a custom extraction from 1findr comprising articles on COVID-19, MERS, SARS and coronaviruses in general.

Centre d’information sur le nouveau coronavirus

This French version of our Novel Coronavirus Information Center includes regular updates on research in French journals.

Call for papers

Various Elsevier journals have special issues related to COVID-19

View more

Content hubs from other publishers

Elsevier is among various publishers who are making relevant papers freely available. Others include: Springer Nature | Wiley | NEJM | BMJ | American Society for Microbiology | American College of Cardiology| Chongqing VIP Information. Many publishers have also signed the Wellcome Trust Statement committing to share relevant nCoV research and data rapidly and openly.

You can find all these publishers and more on LitCovid — the National Library of Medicine's curated hub of scientific literature about novel coronavirus. It currently provides access to more than 3,200 articles in PubMed and is being updated daily.

Early-stage research: preprints on SSRN

Rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.SSRN , Elsevier’s platform for the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.

View coronavirus research on SSRN

Top 10 SSRN downloads of the week*

  1. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study 9,063
  2. Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1 7,435
  3. Effects of BNT162b2 mRNA Vaccination on COVID-19 Disease, Hospitalisation and Mortality in Nursing Homes and Healthcare Workers: A Prospective Cohort Study Including 28,594 Nursing Home Residents, 26,238 Nursing Home Staff, and 61,951 Healthcare Workers in Catalonia 432
  4. Recommendations for the Recognition, Diagnosis, and Management of Patients with Post COVID-19 Condition ('Long COVID'): A Delphi Study 367
  5. Decreased Infectivity Following BNT162b2 Vaccination 144
  6. Myopia Progression in Children During COVID-19 Home Confinement in Argentina 114
  7. 6-Month Follow Up of Hospitalised COVID-19 Patients: A Nationwide Cohort Study of 8679 Patients in Germany 80
  8. Behavioral Nudges Increase COVID-19 Vaccinations: Two Randomized Controlled Trials 74
  9. Safety, Tolerability and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Children and Adolescents: A Randomised, Double-Blind, and Placebo-Controlled, Phase 1/2 Clinical Trial 52
  10. Vaccine Effectiveness of the First Dose of ChAdox1 nCOV-19 and BNT162b2 Against SARS-CoV-2 Infection in Residents of Long Term Care Facilities (VIVALDI Study) 28

* Calculated on Thursday, April 15, 2021

Infographic: Global research trends

Interactive map: global coronavirus experts

This map represents the most active institutions researching COVID-19 and related coronaviruses. We ran a search in Scopus — a source-neutral abstract and citation database of over 75 million records — for publications related to COVID-19, coronaviruses and related diseases such as SARS and MERS. We then used the resulting ~96,000 publications to identify the currently active researchers and institutions that are working in these areas, the map shows the most prolific global institutions and links to their authors. (Updated: June 21, 2021)

Click on a pin to see more about the institution, the numbers of researchers and their publications that matched our query in Scopus. Then link through to the researcher's profiles in Scopus to learn more about their areas of expertise.

Vaccines and drug discovery

© istock.com/FG Trade

Webinar: Demystifying COVID-19 Vaccines

Join John McConnell, Editor-in-Chief of The Lancet Infectious Diseases, and Ylann Schemm, Director of the Elsevier Foundation and Corporate Responsibility at Elsevier, in a conversation about how COVID-19 vaccines work and their safety and efficacy in preventing infection. John will share insights into the public's most frequently asked questions. Join us for an invaluable opportunity to secure answers to your own pressing questions.

Wednesday, April 28, 2021  10am EDT | 2pm GMT | 4pm CET

Register here

Resources

You can find these and more resources on Elsevier's COVID-19 Healthcare Hub Vaccine Toolkit

New research

A new clinical preprint (not yet peer-reviewed) posted on SSRN highlights the immunogenicity and efficacy of the Oxford/AstraZeneca vaccine as well as the potential for a substantial reduction in transmission. This study has been covered by various news outlets, including the BBC | BBC Health | CNN | Bloomberg | Financial Times

You can search for vaccine studies in our Research section.

R&D tool to capture clinical trial data is free for researchers studying COVID-19

Elsevier recently launched Veridata Electronic Data Capture (EDC), which enables clinical researchers to capture clinical trial data in a secure environment. To assist researchers working to develop vaccines and other therapies for COVID-19, Elsevier has pledged to make Veridata EDC available for free. Interested clinical researchers can contact Elsevier customer support via e-mail at covid19@elsevier.com and apply for a demo account. Following the necessary compliance training, they will receive a free 12-month license. Read the press release

Gender and COVID-19 Group on Mendeley

This collection of research, studies and other references covers the sex and gender dimensions of the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. The library is a public group, free for anyone in the world to join, access and add. References - articles, preprints, news articles, blog posts, magazine articles, reports, etc - include those compiled by Dr. Rosemary Morgan at Johns Hopkins University and colleagues from the Gender and COVID-19 Working Group, as well as those from other compilations and sources. The library on the Mendeley platform includes >500 references related to Gender and COVID-19, as well as gender and other infectious disease/epidemics, which you can locate and find resources, include direct citations and references within your work, and add additional references & folders directly to the group. We invite the community to continue posting new references as they’re published/become available even if also being added to an existing compilation elsewhere.

COVID-19 drug therapy — updated on October 26

Pharmacists in Elsevier's Clinical Solutions group write about potential treatment options for COVID-19. Read their paper.

Drug information from Elsevier's R&D Solutions

Elsevier's R&D solutions for pharma and life sciences integrate data, analytics and technology to help researchers make data-driven drug discovery and development decisions and streamline literature monitoring for pharmacovigilance. Here, we use those tools to generate information relevant to combating COVID-19:

Mayo Clinic Proceedings: Possible COVID-19 Pharmacotherapies and QTc/TdP Liability

The Mayo Clinic Proceedings journal has released a pre-proof of a new paper titled Possible COVID-19 Pharmacotherapies and QTc/TdP Liability. From the abstract: "As the COVID-19 global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the “off label” re-purposing of drugs such as hydroxychloroquine and lopinavir/ritonavir with the potential for unwanted QT interval prolongation, and a risk of drug induced sudden cardiac death. With the possibility that a significant proportion of the world’s population could receive soon COVID-19 pharmacotherapies with torsadogenic potential for therapy or post-exposure prophylaxis, this document serves to help healthcare providers mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk to personnel of COVID 19 exposure and conserving the limited supply of personal protective equipment. Read the paper

Pure portal: Discover research collaborators and institutions globally

Use this Pure portal to discover novel coronavirus related research collaborators and institutions around the world. It uses Elsevier’s Natural Language Fingerprinting technology, scientific taxonomies and Scopus profiles and can be used to filter and find associated publications.

Additional information and examples


Public health

Here, you will find guidance and commentary from experts along with official guidance from major health organizations such as the CDC and WHO. For research on public health and related topics, see our Research section.

Research!America webinar

COVID-19 treatments exemplify the significance of public-private sector R&D but haven't received the same attention as vaccines, creating possible knowledge gaps. This free Research!America webinar — Science v Covid-19: Promising Treatments Explained (recorded on Feb 25, 2021) — features expert panelists including Dr Rajesh T. Gandhi Infectious Diseases Society of America; Dr James L. Madara, CEO and EVP American Medical Association (AMA); Denise Brooks-Williams, Senior VP and CEO North Market, Henry Ford Health System; Dr Michael Ybarra, MD, VP and Chief of Medical Affairs, PhRMA. Register to view on demand

Free on demand: 14th Vaccine Congress Online Edition

Elsevier's 14th Vaccine Congress – Online Edition: Combatting the threat of Covid-19, held in September 2020, featured leading experts in vaccinology sharing their knowledge on the current developments and challenges we face. Sessions are available free on demand. Register here

Dr. Fauci features Cell paper in Congressional hearing

Studies to improve face masks and disinfect the air

Special issue: Bioaerosol and infectious diseases

This special issue in the Journal of Aerosol Science, from 2018, has articles that are relevant to COVID-19.

COVID-19 Pandemic Collection in AJPM

COVID-19 Data Insights Map by LexisNexis Risk Solutions

By combining their data and analytics with those of other industry stakeholders, LexisNexis Health Care created a COVID-19 dataset and interactive visualization to provide insights on at-risk populations and care capacity risks. View the map

Progress in Disaster Science: COVID-19 Special Collection

Keeping wider disciplinary involvement in mind, the journal Progress in Disaster Science plans to publish special issues as a major learning from the evolving nature of the pandemic. Papers on the following topics related to COVID-19 response are encouraged: public health response, governance and policy analysis, emerging technologies, roles of civil societies and other stakeholders, citizen participation, collateral hazards, business continuity, recovery planning, economic/fiscal implications. Read the special collection

Journal of Aerosol Science: Special section on "Virus Aerosol Science, Sampling, and Control"

The editor, Prof. Chris Hogan, writes: "The Journal of Aerosol Science has long been a resource on understanding viruses in aerosols, methods to sample airborne viruses, and to control and inactivate airborne viruses. In this collection, we highlight numerous studies over the past decade focusing on virus aerosol science. In addition, we invite authors to contribute this virtual collection by submitting to this journal, selecting the option: "SARS-CoV-2 & Virus Aerosols." Read the special section

COVID-19 podcasts and webinars by CIDRAP

Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here

Patient resources

عدوى فيروس كورونا المستجد (patient education in Arabic)

عدوى فيروس كورونا المستجد

Elsevier's Patient Access Program for research

With our Patient Access Program, patients and their caregivers can receive medical or healthcare related research papers by emailing patientaccess@elsevier.com. This email is constantly monitored by our support teams, who aim to provide individual articles at no cost to patients and caregivers within 24 hours. Requesters simply need to include the article title and authors, date published, and/or the DOI or URL if available so we can locate the article as quickly as possible. Learn more

COVID-19 podcasts and webinars

Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here

More resources


Usage notice

Since January 2020, Elsevier has created an online resource center with free information in English and Mandarin on the novel coronavirus (COVID-19).

This Novel Coronavirus Information Center is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource center — including this research content — immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource center remains active.